Ilya Ivlev News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Author summary Why was this study done? ➢ Clinicians and researchers depend on the peer-reviewed literature for accurate assessments of drug efficacy and safety, but this depends on whether the outcomes of all trials—negative, as well as positive—are reported transparently. ➢ In an earlier study, using Food and Drug Administration (FDA) review documents as a gold standard, we found that many negative trials had been misreported in the published literature as having positive outcomes or had simply not been published. ➢ Since then, reporting bias has been the subject of additional studies and policy changes, raising the question, Is the antidepressant literature now being reported more transparently? What did the researchers do and find? ➢ Using FDA reviews on 4 newer antidepressants, we identified 30 trials, half with positive, and half with negative, outcomes. ➢ Among the 15 negative trials, 6 were unpublished and 2 others were misre ....

United States , Ilya Ivlev , Aarons Kesselheim , Angelini Pharma , Kathryn Burrows , Sepideh Alavi , Ryan Mckenna , Yusuki Ogawa , Drug Administration , International Committee Of Journal Editors , Oxford Health Biomedical Research Centre , National Institute For Health Research , International Clinical Trials Registry Platform , Drug Administration Amendments Act , Harvard University , Incipit Italian Network For Paediatric Trials , University Of Bern , Oxford Cognitive Health Clinical Research Facility , Thames Valley Applied Research Collaboration , Research Professorship , Drug Administration Amendments , Creative Commons , Supporting Information , Medical Officer , National Institute , Health Research ,